Evidence map›Paper›PMID 40075594›Full record

ArticleCancers2025

Residual Tumour at CT Scan Based on Radiologic Peritoneal Carcinomatosis Index After Optimal Cytoreduction in Advanced Ovarian Cancer: A True Prognostic Factor.

Alexandra Trelis Blanes, Víctor Lago, Rosario Pérez Martínez, Vicente Belloch Ripollés, Guillermina Montoliu, Pablo Padilla-Iserte, Marta Gurrea, Jose Miguel Cárdenas Rebollo, Santiago Domingo

Abstract read
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alexandra Trelis BlanesDepartment of Gynaecologic Oncology, University Hospital La Fe, 46026 Valencia, Spain.ORCID 0000-0001-6208-5319
Víctor LagoDepartment of Gynaecologic Oncology, University Hospital La Fe, 46026 Valencia, Spain.
Rosario Pérez MartínezDepartment of Radiology, University Hospital La Fe, 46026 Valencia, Spain.
Vicente Belloch RipollésDepartment of Radiology, University Hospital La Fe, 46026 Valencia, Spain.
Guillermina MontoliuDepartment of Radiology, University Hospital La Fe, 46026 Valencia, Spain.
Pablo Padilla-IserteDepartment of Gynaecologic Oncology, University Hospital La Fe, 46026 Valencia, Spain.ORCID 0000-0003-0524-6213
Marta GurreaDepartment of Gynaecologic Oncology, University Hospital La Fe, 46026 Valencia, Spain.
Jose Miguel Cárdenas RebolloDepartment of Applied Mathematics and Statistics, CEU San Pablo University, 28003 Madrid, Spain.ORCID 0000-0002-3093-1688
Santiago DomingoDepartment of Gynaecologic Oncology, University Hospital La Fe, 46026 Valencia, Spain.ORCID 0000-0002-8355-3369

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe maximum residual tumour size after surgery is the most important prognostic factor related to survival in advanced ovarian cancer. This parameter can be subjectively determined by the surgeon at the end of the operation and by a radiologist with a postoperative CT scan. CT scans after optimal cytoreduction can reveal residual/progressive disease in a significant percentage of patients, ranging from 21% to 49%. The aim of this study was to validate the PCI scale for the systematic reading of postoperative CT scans in patients with advanced ovarian cancer and to establish it as a new prognostic marker. MATERIAL AND

methodsPatients with advanced ovarian cancer (FIGO II-IV), diagnosed between 2007 and 2019 in Hospital La Fe Valencia, in whom cytoreductive surgery was performed (achieving R0 or R1), and in whom a postoperative CT scan was performed between the third and eighth week post-surgery and prior to the start of chemotherapy, were included. Two different radiologists who specialised in gynaecological malignancy performed a blind analysis of the CT scans. They then read the images using the Peritoneal Carcinomatosis Index (PCI) scale, which divides the abdominopelvic cavity into 12 quadrants. Using the Qualitative Assessment (QA) scale, they established the presence or lack of tumour disease in each of these regions, with QA 1-2 being definitely/probably normal, QA 3 indeterminate and QA 4-5 probably/definitely metastatic.

resultsThis study included a cohort of 117 patients. The radiological study found measurable tumour disease in up to 49% of patients after optimal primary cytoreduction (R0 or R1). There was "substantial agreement" between the results of the two radiologists according to the Kappa analysis (0.624). Both radiologists' (A and B) findings were related to a significant reduction in both disease-free survival (DFS) and overall survival (OS) in patients with residual disease in the CT scan (QA 4-5) versus those without macroscopic disease (QA 1-3) (

conclusionsThe finding of radiological tumour disease on a standardised and systematised postsurgical CT scan prior to the initiation of adjuvant chemotherapy is associated with the prognosis of patients with advanced ovarian cancer.

Indexed as

advanced ovarian cancerCT scanoptimal cytoreductionPCI radiologistprognosisresidual disease

Identifiers

PMID40075594
PMCPMC11899235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.